Annals of Oncology 13:1264-1274, 2002
© 2002 European Society for Medical Oncology
Original Paper |
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study
1 Wessex Medical Oncology Unit, Royal South Hants Hospital, Southampton, UK; 2 Cancer Division, MRC Clinical Trials Unit, London, UK; 3 Lymphoma Department A, Centre of Oncology, M.Sklodowska-Curie Memorial Institute, Warsaw, Poland; 4 Clinical Haematology & Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia; 5 Department of Haematology, John Radcliffe Hospital, Oxford, UK; 6 Ospedale Generale Regionale Bolzano, Bolzano, Italy; 7 Department of Haematology/Ematologica, Ospedale Cervello, Palmero, Italy; 8 Department of Haematology, Singleton Hospital, Swansea, UK; 9 Department of Clinical Haematology & Medical Oncology, Box Hill Hospital, Victoria, Australia; 10 Electron Microscopy, Southampton General Hospital, Southampton, UK
Received 11 February 2002; accepted 26 February 2002
Background:
Burkitt’s lymphoma (BL) is a rare and rapidly progressive form of B-cell non-Hodgkin’s lymphoma. Cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate (CODOX-M)/ifosfamide, etoposide and high-dose cytarabine (IVAC) is a highly effective alternating non-cross-resistant regimen developed by Magrath et al. (Magrath I., Adde M., Shad A. et al. J Clin Oncol 1996; 14: 925–934) at the US National Cancer Institute. The aim was to confirm these results in a larger, international, multi-centre study using International Prognostic Index-based criteria to assign prognostic groups, whilst slightly simplifying the protocol.
Patients and methods:
A phase II study where: (i) low risk (LR) patients were treated with three cycles of modified CODOX-M; and (ii) high risk (HR) patients received treatment with four cycles of alternating modified CODOX-M and IVAC chemotherapy. Target of 60 patients, fit for protocol treatment, from 16 to 60 years of age with locally diagnosed, non-HIV-related, non-organ-transplant-related BL.
Results:
Results are given for 52 of 72 registered patients whose pathological eligibility was confirmed by central pathology review: 12 LR plus 40 HR. The majority of patients (n = 41) completed protocol treatment, but toxicity was severe, especially myelosuppression and mucositis. Overall, 2-year event-free survival (EFS) was 64.6% (95% CI 50.4% to 78.9%) and 2-year overall survival (OS) was 72.8% (95% CI 59.4% to 86.3%). For LR, 2-year EFS was 83.3% and OS was 81.5%. For HR, 2-year EFS was 59.5% and OS was 69.9%.
Conclusions:
This study confirms high cure rates with this CODOX-M/IVAC approach.
Key words: Burkitt’s lymphoma, chemotherapy, CODOX-M, IVAC
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Tholouli, S. Watt, G. S. Lucas, J. Burthem, J. A. L. Yin, J. Cavet, H. Greenfield, and J. B. Houghton Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome Blood, July 9, 2009; 114(2): 485 - 486. [Full Text] [PDF]
|
|
|
|
|
|
G. M. Mead, S. L. Barrans, W. Qian, J. Walewski, J. A. Radford, M. Wolf, S. M. Clawson, S. P. Stenning, C. L. Yule, A. S. Jack, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial) Blood, September 15, 2008; 112(6): 2248 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Perkins and J. W. Friedberg Burkitt Lymphoma in Adults Hematology, January 1, 2008; 2008(1): 341 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Galicier, C. Fieschi, R. Borie, V. Meignin, M.-T. Daniel, L. Gerard, and E. Oksenhendler Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study Blood, October 15, 2007; 110(8): 2846 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Dawson, A.P. Schwarer, C. McLean, P. Oei, L.J. Campbell, E. Wright, J. Shortt, and A.M. Street Aids-related plasmablastic lymphoma of the oral cavity associated with an IgH/MYC translocation treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A Haematologica, January 1, 2007; 92(1): e11 - e12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Venugopal and S. A. Gregory Lymphoproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 265 - 297. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Dave, K. Fu, G. W. Wright, L. T. Lam, P. Kluin, E.-J. Boerma, T. C. Greiner, D. D. Weisenburger, A. Rosenwald, G. Ott, et al. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med., June 8, 2006; 354(23): 2431 - 2442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Divine, P. Casassus, S. Koscielny, J. Bosq, C. Sebban, C. Le Maignan, A. Stamattoulas, B. Dupriez, M. Raphael, J.-L. Pico, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol Ann. Onc., December 1, 2005; 16(12): 1928 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Ansell and J. Armitage Non-Hodgkin Lymphoma: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2005; 80(8): 1087 - 1097. [Abstract] [PDF]
|
|
|
|
|
|
K. A. Blum, G. Lozanski, and J. C. Byrd Adult Burkitt leukemia and lymphoma Blood, November 15, 2004; 104(10): 3009 - 3020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Smeland, A. K. Blystad, S. O. Kvaloy, I. M. Ikonomou, J. Delabie, G. Kvalheim, J. Hammerstrom, G. F. Lauritzsen, and H. Holte Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens Ann. Onc., July 1, 2004; 15(7): 1072 - 1078. [Abstract] [Full Text] [PDF]
|
|